The study published by Bastiaan M Privé and colleagues in The Lancet Oncology represents, to our knowledge, the first randomised phase 2 trial evaluating lutetium-177–PSMA-617 (177Lu-PSMA-617) in ...
Dr. Morris then discussed the PCWG4 Rule of 5 for defining radiographic progression free survival in the post-flare period. If there are <=5 new metastases, a confirmatory scan is performed, and if ...
March 9, 2007 -- A new analysis that compared 3 common treatment options for prostate cancer found a difference between them. Men who were treated with external-beam radiotherapy did not live as long ...
Joseph J. Busch, Jr., M.D. , a board-certified radiologist and Founder of the Busch Center in Alpharetta, GA, will give a presentation titled "Robotic Assisted MRI-Guided Transurethral Ultrasound ...
At the recent American Urological Association (AUA) annual meeting, focal therapies for localized prostate cancer took center stage, moving from a niche option to a recognized alternative to surgery ...
Johnson & Johnson (NYSE:JNJ) has entered a clinical supply agreement with GI Innovation to test a bispecific immunotherapy ...
MedPage Today on MSN
PSMA-PET cuts need for biopsy in suspected prostate cancer
But does it cost too much?
Add Yahoo as a preferred source to see more of our stories on Google. Xofigo and Xtandi as a combination therapy in mCRPC has demonstrated a significant OS benefit over Xtandi alone in an investigator ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results